Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

Spravato is now the first-ever stand-alone therapy for treatment-resistant depression, and is on its way to becoming a ...

The U.S. Food and Drug Administration on Tuesday approved the first nasal spray that will help with treating major depressive ...

Johnson & Johnson has announced that the U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal ...

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...

The spray, called Spravato, is now the first-ever standalone therapy for treatment-resistant depression, which is when trying at least two standard treatments does little to nothing to improve ...

Johnson & Johnson (JNJ) said Tuesday that the US Food and Drug Administration approved nasal spray Spravato as the first-ever stand-alone therapy for major depressive disorder. The product, which ...

President Donald Trump has signed an executive order promising to eliminate what he incorrectly labels “the electric vehicle ...

School administrators and nurses are encouraged to review applicable state laws and regulations to ensure neffy® (epinephrine nasal spray) 2 mg ...

Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the ...

The Food and Drug Administration has approved Johnson & Johnson's nasal spray Spravato (esketamine) as a standalone treatment ...

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...